Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroartemisinin-piperaquine for uncomplicated falciparum and vivax malaria in Indonesia
ACTRN12616001533482Phase 4Not yet recruiting
- Sponsor
- Ministry of Health
- Start
- Dec 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dihydroartemisinin and piperaquine in Malaria and malaria, sponsored by Ministry of Health. Primary endpoints: Treatment failure rate and Adequate clinical and parasitological response. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
dihydroartemisininpiperaquine
03
Conditions
Malariamalaria
Beyond the preview
Go deeper on ACTRN12616001533482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001533482.